Table 1.
Randomly selected beta cell autoantibody positive and negative individuals from the Action LADA cohort (n = 1114), grouped according to binding patterns of f-GADA and t-GADA. Data are presented as median (IQR) or n (%)
| Beta cell autoantibody positive | Beta cell autoantibody negative | f-GADA negative, t-GADA negative | f-GADA positive, t-GADA negative (restricted) | f-GADA positive | t-GADA positive | f-GADA positive, t-GADA positive | |
|---|---|---|---|---|---|---|---|
| Samples, n | 511 | 603 | 628 | 55 | 478 | 431 | 423 |
| Female, n (%)a | 264 (51.9) | 281 (46.6) | 289 (46.0) | 24 (43.6) | 251 (52.7) | 232 (54.1) | 227 (53.9) |
| Male, n (%)a | 245 (48.1) | 322 (53.4) | 339 (54.0) | 31 (56.4) | 225 (47.3) | 197 (45.9) | 194 (46.1) |
| Age (years) | 49.3 (40.7–58.2) | 50.8 (41.7–58.6) | 51.2 (41.9–58.7) | 54.2 (43.6–62.5) | 49.0 (40.2–57.6) | 48.2 (39.8–57.4) | 48.2 (39.7–57.2) |
| Age at onset (years) | 47.6 (38.6–56.0) | 48.9 (40.3–56.6) | 48.9 (40.5–56.7) | 52.0 (41.8–59.8) | 47.0 (38.4–55.7) | 46.6 (38.0–55.5) | 46.4 (37.9–55.1) |
| Duration of disease (years) | 2.0 (0.8–3.6) | 1.8 (0.5–3.5) | 2.0 (0.5–3.5) | 1.8 (0.3–3.10) | 2.0 (0.7–3.5) | 2.0 (0.8–3.5) | 2.0 (0.8–3.5) |
| BMI (kg/m2)b | 26.0 (22.9–30.1) | 29.5 (26.6–33.8) | 29.7 (26.6–34.1) | 29.9 (26.7–35.9) | 25.6 (22.8–29.4) | 24.9 (22.6–28.8) | 24.8 (22.6–28.8) |
| Individuals on insulin, n (%)c | 238 of 487 (48.9) | 120 of 558 (21.5) | 126 of 587 (21.5) | 7 of 51 (13.7) | 231 of 451 (51.2) | 225 of 407 (55.3) | 224 of 400 (56.0) |
Missing information for asex (n = 2), bBMI (n = 55), cdiabetes treatment (n = 69)